JESSICA ROBBINS: Open Payments
NPI 1447725080 · MONTGOMERY, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$712 in 28 payments from 8 companies in 2025. Trend: 2023 $205 · 2024 $524 · 2025 $712
Food & beverage: $712
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $207 |
| ABBVIE INC. | 10 | $153 |
| Axsome Therapeutics, Inc. | 5 | $143 |
| Lilly USA, LLC | 1 | $111 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Boston Scientific Corporation | 1 | $23 |
| GlaxoSmithKline, LLC. | 1 | $15 |
Products named: BREZTRI, Auvelity, VRAYLAR, ZEPBOUND, UBRELVY, AIRSUPRA, CAPLYTA, REXULTI.
Industry payments across AL — which companies pay providers there.
